FDA Approves New Hepatitis C Treatment

The U.S. Food and Drug Administration on Nov. 22 announced the approval of Olysio (simeprevir) to treat chronic hepatitis C virus infection.

The U.S. Food and Drug Administration has approved Olysio (simeprevir) for treatment of chronic hepatitis C virus infection, a disease that can lead to diminished liver function or liver failure. Most people infected with the virus have no symptoms of the disease until liver damage becomes apparent, which may take several years, and most of them then develop chronic hepatitis C. Some will develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice, infections. or liver cancer.

According to the Centers for Disease Control and Prevention, about 3.2 million Americans are infected with the hepatitis C virus.

Olysio is a protease inhibitor that blocks a specific protein needed by the hepatitis C virus to replicate. It is to be used as a component of a combination antiviral treatment regimen and is intended for adults with compensated liver disease (a diseased liver that is still functioning), including cirrhosis, who have not received treatment for their infection or for whom previous treatment has not been effective, according to FDA's announcement.

"Olysio is the third FDA-approved protease inhibitor to treat chronic hepatitis C virus infection, and provides health professionals and patients with a new, effective treatment for this serious disease," said Dr. Edward Cox, M.D., director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. The others, approved in 2011, are Victrelis (boceprevir) and Incivek (telaprevir).

Olysio was reviewed under FDA's priority review program, which provides for an expedited review of drugs that, if approved, would provide safe and effective therapy when no satisfactory alternative therapy exists or offer significant improvement compared to available therapies.

Olysio is marketed by Janssen Pharmaceuticals, based in Raritan, N.J.; Victrelis is marketed by Whitehouse Station, N.J.-based Merck; and Incivek is marketed by Cambridge, Mass.-based Vertex Pharmaceuticals.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Get the Ultimate Guide to OSHA Recordkeeping

    When it comes to OSHA recordkeeping there are always questions regarding the requirements and in and outs. IndustrySafe is here to help. We put together this page with critical information to help answer your key questions about OSHA recordkeeping.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We put together a guide that’s easy to digest so you can ensure you're complying with OSHA's training standards.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Track Key Safety Performance Indicators

    IndustrySafe’s Dashboard Module allows organizations to easily track safety KPIs and metrics. Gain increased visibility into your business’ operations and safety data.

  • Industry Safe
comments powered by Disqus